Reported 10 days ago
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Buy rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), despite lowering the price target from $90 to $80. Concurrently, J.P. Morgan also supports a Buy rating, setting a higher target at $119. Recent updates from BioMarin’s studies at the ASBMR Annual Meeting indicate promising advancements in treatment efficacy for young patients. Analysts remain optimistic about BioMarin’s growth potential, especially with upcoming product expansions.
Source: YAHOO